The present hypothesis was to identify the potential of sorafenib tosylate (ST) loaded liposomal dry powder inhaler (ST-LDPI) for targeting non-small cell lung cancer (NSCLC). ST-LDPI was obtained by spray drying the ST loaded liposomes, evaluated for physicochemical properties and in vitro lung deposition by Andersen Cascade Impactor (ACI). Optimized liposomal formulation showed the particle size, zeta potential, encapsulation efficiency and drug content of 111.15 ± 1.03 nm, −29.87 ± 0.56 mV, 93.13 ± 1.11% and 84.47 ± 1.28%, respectively. Furthermore, ST-LDPI exhibited low density and good flowability. FESEM confirmed the spherical nature of particles with mean size of 3.15 ± 0.51 μm. The DSC and FTIR spectra revealed complete encapsulation of ST. Further, the PXRD showed reduced crystallinity ST. In vitro deposition demonstrated the fine particle fraction of 83.7 ± 0.09%, recovery of 95.43 ± 0.03%, mean mass aerodynamic diameter 3.15 ± 0.2 µm, geometric standard deviation 1.78 ± 0.15 µm and 85 ± 0.1% dispersibility. The In vitro drug release revealed biphasic release pattern, burst release in the first 6 h followed by sustained release up to 72 h. Hence this novel approach could be a targeted delivery of ST to the NSCLC treatment.
15 February 2021 in Future Journal of Pharmaceutical Sciences
Background: Resveratrol, a bioactive phytoconstituent, is used to treat chronic respiratory diseases. However, its clinical application was hampered due to its poor bioavailability. In the present study, controlled release of resveratrol loaded nanocochleate-based dry powder inhaler was investigated to improve its biopharmaceutical properties for pulmonary drug delivery. The in vivo toxicity study was performed in the healthy male albino Wistar rats by intracheal administration.Results: Resveratrol loaded nanocochleate-based dry powder inhaler was prepared by lyophilizing the resveratrol loaded dimyristoylphosphatidylcholine sodium and calcium ion-based nanocochleates using mannitol as cryoprotectant. Resveratrol loaded nanocochleates showed a particle size and encapsulation efficiency of 329.18 ± 9.43 nm and 76.35 ± 3.65%, respectively. Resveratrol loaded nanocochleate-based dry powder exhibited a particle size of 102.21 ± 9.83 μm and satisfactory flowability with initial burst release followed by extended release up to 96 h. The in vitro drug deposition pattern using multistage cascade impactor showed 1.28-fold improvement in fine particle dose, and the in vivo toxicity potential by histopathological study in albino rats revealed safety of formulation.Conclusions: Resveratrol loaded nanocochleate-based dry powder inhaler could serve as an efficient delivery system for the treatment of chronic respiratory diseases.Graphical
6 December 2023 in Therapeutic Innovation & Regulatory Science
Methotrexate (MTX), a biopharmaceutical classification system-IV anticancer drug, exhibits low therapeutic efficacy. Moreover, its clinical applications were restricted due to its multidrug resistance (MDR) in cancer and its toxic effects. The present investigation was to fabricate 1, 2-dimyristoyl-sn-glycero-3-phospho-rac-(1-glycerol) sodium (DMPG-Na), (3β)-cholest-5-en-3-ol (cholesterol) and calcium-based nanocochleates (NCs) as a potential oral delivery carrier for MTX to enhance its therapeutic efficacy with low toxicity. MTX-loaded NCs (MTX-NCs) was developed by the addition of calcium ion into preformed nanoliposomes (MTX-NLs) comprising MTX, DMPG-Na, with cholesterol and evaluated by in-vitro and in-vivo methods in comparison with MTX-NLs and pure MTX. Stable tubular rod structure of MTX-NCs possessing particle size, encapsulation efficiency and zeta potential of 374.1 ± 2.2 nm, 78.63 ± 2.12% and −71.2 mV, respectively were obtained from homogenous unilamellar, discrete and spherical structured MTX-NLs with a diameter and zeta potential of 363.3 ± 3.7 nm and −74.6 mV respectively. A thermal study revealed an amorphous state of MTX in MTX-NCs. Pharmacokinetics study in rats, MTX-NLs and MTX-NCs were showed controlled release with 5 and 6 fold improvements in oral bioavailability. Moreover, MTX-NCs showed low tissue distribution. These results collectively suggest that the developed system could be used to improve the therapeutic efficacy of MTX.